That makes sense.
However I have a further question that someone may have some suggestions.
I also note that we are doing further safety trials at higher doses just in case the higher doses may be required. Is this SOP or does it maybe signal that there is a question about effecasy at the existing trial dosage?? If it is standard procedure then there is no message to be gained except that congratulations for diligence. If not standard then is there something we will get to know at Q2 results?
Ann: DSMB again reaffirms XanADu trial to continue without change, page-49
-
- There are more pages in this discussion • 3 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add ACW (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
2.4¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.98M | |||
| Open | High | Low | Value | Volume |
| 2.4¢ | 2.5¢ | 2.3¢ | $146.4K | 5.980M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 7 | 1293461 | 2.4¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 2.5¢ | 336163 | 5 |
View Market Depth
| Last trade - 16.10pm 12/11/2024 (20 minute delay) ? |
| ACW (ASX) Chart |